Attomarker
Griff Williams has a diverse background in investment management and agriculture investments. Griff is currently the Director and Chief Investment Officer of Agricultural Investments at Future Planet Capital, a position they have held since November 2021. Prior to this, Griff was a Director at Waitonui Milltrust Agricultural Holdings starting from August 2018. Griff also held positions as Director at Attomarker Ltd and Roslin Technologies in 2017.
Griff's work experience includes being the Chief Investment Officer and Co-Founder of Milltrust Agricultural Investments from January 2014 onwards, where they focused on making agriculture investment portfolios accessible to institutional investors. Griff has also held roles at Itaú UK Asset Management as Head of Europe, Institutional and Head of International Product Strategy, and as an Investment Management Professional at an Independent firm.
Earlier in their career, Griff worked as an Institutional Solutions Strategist at Pioneer Investments from July 2006 to July 2010, where they developed and commercialized diversified multi-asset and fixed income strategies. Griff also has experience as a Senior Investment Manager at Railpen Investments, where they managed global equity funds and negotiated investment management agreements. Prior to that, Griff was the Head of Manager Research at Gissings Consultancy Services, where they designed and implemented the fund manager research process.
Throughout their career, Griff has demonstrated expertise in agriculture investments, institutional investment strategies, and asset allocation advice. Griff has contributed thought leadership to the institutional investor community and has a strong background in research and portfolio management.
Griff Williams began their education at King's College Auckland from 1980 to 1984. Although no degree or field of study was specified, their time in this institution provided him with a foundation for their future educational pursuits.
From 1985 to 1988, Williams attended Victoria University of Wellington, where they pursued a Bachelor of Commerce and Administration degree. During their time at this university, they focused their studies on the subjects of Business Administration and Political Science.
Following their undergraduate studies, Williams furthered their education by obtaining a Chartered Financial Analyst (CFA) designation from 1997 to 2000. Griff engaged in comprehensive coursework and training in the field of finance, earning proficiency in the various areas covered by the CFA program.
Overall, Griff Williams has a diverse educational background ranging from their initial years at King's College Auckland to obtaining a degree from Victoria University of Wellington and finally earning a CFA designation.
This person is not in any teams
This person is not in any offices
Attomarker
Attomarker is a spin-out company from the University of Exeter, a member of the UK’s Russell Group of research-intensive universities. The company’s founder, Professor Andrew Shaw, leads a team of scientists and engineers across the UK & Germany. Backed by six patents and referenced in 17 academic journals, Attomarker works. Realising thevision that has inspired many, but has, until now, proved so hard to turn into reality. Patented Attomarker technology collects the blood on a disposable credit-card sized chip which slots into a mobile pocket-sized devise, docked to an iPhone. The camera visualises the blood tests which are then interpreted by the iPhone. Test results can be shared, linked to electronic patient record systems and an AI Symptom checker for diagnosis. A tele-consultation will be available via the phone. Planned launch tests include Food Allergy (covering the eight food allergens that account for 95% of all), Pregnancy (replacing unreliable and undignified urine tests) and C-reactive protein, the 21st C thermometer, (identifying infection faster than changes in temperature). Research projects that will follow include fifth generation HIV testing, infectious diseases such as Zika and Ebola, Alzheimer’s, immunotherapy cohort surveillance, sepsis and a vitamin panel test. Attomarker intends to develop three sales channels - private doctors, pharmacies and direct to consumer.